Please use this identifier to cite or link to this item:
|Title:||Why breast cancer signatures are no better than random signatures explained||Authors:||Goh, Wilson Wen Bin
|Keywords:||Science::Biological sciences||Issue Date:||2018||Source:||Goh, W. W. B., & Wong, L. (2018). Why breast cancer signatures are no better than random signatures explained. Drug Discovery Today, 23(11), 1818-1823. doi:10.1016/j.drudis.2018.05.036||Journal:||Drug Discovery Today||Abstract:||Random signature superiority (RSS) occurs when random gene signatures outperform published and/or known signatures. Unlike reproducibility and generalizability issues, RSS is relatively underexplored. Yet, understanding it is imperative for better analytical outcome. In breast cancer, RSS correlates strongly with enrichment for proliferation genes and signature size. Removal of proliferation genes from random signatures reduces the predictive power of random signatures. Almost all genes are correlated to a certain extent with the proliferation signature, making complete elimination of its confounding effects impossible. RSS goes beyond breast cancer, because it also exists in other diseases; it is especially strong in other cancers in a platform-independent manner, and less severe, but present nonetheless, in nonproliferative diseases.||URI:||https://hdl.handle.net/10356/137544||ISSN:||1359-6446||DOI:||10.1016/j.drudis.2018.05.036||Rights:||© 2018 Elsevier Ltd. All rights reserved. This paper was published in Drug Discovery Today and is made available with permission of Elsevier Ltd.||Fulltext Permission:||open||Fulltext Availability:||With Fulltext|
|Appears in Collections:||SBS Journal Articles|
Files in This Item:
|Breast Cancer Signatures Are No Better Than Random Signatures Explained.pdf||664.22 kB||Adobe PDF||View/Open|
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.